Cytokeratin 19 Antibody (DA043)

Description

Anti-cytokeratin 19 reacts with simple and complex epithelia, including the glandular and ductal epithelium of organs such as the gastrointestinal tract and breast and squamous epithelium. CK19 expression is seen in many carcinomas, including carcinomas of the colon, stomach, pancreas, biliary tract, liver, and breast.1 Anti-cytokeratin 19 has been used to help identify neoplasms in the liver1 and as an aid in the identification of thyroid papillary carcinoma.2-3 — Références — 1. Jain, Richa et al. "The use of Cytokeratin 19 (CK19) immunohistochemistry in lesions of the pancreas, gastrointestinal tract, and liver." Applied immunohistochemistry & molecular morphology : AIMM vol. 18,1 (2010): 9-15. 2. Rosai, Juan. "Immunohistochemical markers of thyroid tumors: significance and diagnostic applications." Tumori vol. 89,5 (2003): 517-9. 3. de Matos, L.L. et al. "Expression of ck-19, galectin-3 and hbme-1 in the differentiation of thyroid lesions: systematic review and diagnostic meta-analysis." Diagnostic Pathology vol. 7,1 (2012): 97

Caractéristiques

Type

Recombinant monoclonal mouse antibody

Clone

DA043

Isotype

Mouse

Réactivité

Synthetic peptide of human Cytokeratin 19

Localisation

Cytoplasm

Usage prévu

IHC (FFPE)